Stem cell therapies work via signals, not engraftment

For years, the assumption was that transplanted stem cells would settle into damaged tissue, develop into new cells, and drive repair from within. That picture has turned out to be largely incorrect. In practice, injected cells often survive only briefly. Yet some therapies do work: they suppress chronic inflammation for months at a time. How?

The answer lies in what is called paracrine signaling: during the short time they survive, transplanted cells secrete a range of biologically active molecules, including growth factors, anti-inflammatory agents, and small vesicles filled with genetic material (extracellular vesicles). These substances alter the behavior of native cells in the surrounding tissue. The researchers describe this in a review published in the journal Science Bulletin.

Wide variation in outcomes

The most commonly used stem cells in clinical settings are mesenchymal stem cells (MSCs), derived from bone marrow, fat tissue, or umbilical cord blood. They are relatively easy to grow and have proven safe. But clinical results vary considerably. Some patients benefit noticeably, others barely at all. That variation depends on how cells are produced, which donor they come from, and the disease environment in the recipient’s body.

This variability is one of the biggest barriers to wider adoption. The review argues that the field needs a strategic shift: from transplanting cells to directly manufacturing secretomes (the substances cells secrete) or extracellular vesicles, without using the cells themselves. This could make therapeutic effects more reproducible.

What does this mean for the future?

For people considering stem cell therapy today, the picture is nuanced. Some indications, such as dampening chronic inflammation in certain autoimmune conditions, show reasonably consistent results. Effects on organ regeneration or specific degenerative diseases are far less predictable. The field is moving toward cell-free therapies based on what cells produce. That is a promising direction, but not yet widely available in clinical practice.

Read the original article